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           Diabetes mellitus is a metabolic disease characterized by hyperglycemia that 
affects 30 million children and adults in the United States alone. Patients suffering from 
diabetes have high concentrations of reactive α-dicarbonyls (α-DCs) like, methylglyoxal 
(MGO).  The abundance of α-DCs form advanced glycation end products (AGEs); in 
turn, the accumulation of AGEs has been linked to secondary complications. Secondary 
complications include diabetic neuropathy, nephropathy and cardiomyopathy. A recently 
discovered TRPA-1-Nrf-2 pathway is a conserved mechanism in vertebrates and 
invertebrates that detoxifies α-DCs; however, regulators that activate the detoxification 
mechanism are currently unknown. Several supplement grade compounds were screened 
for TRPA-1-Nrf2 induced activity in Caenorhabditis elegans. The drug screen revealed 
several candidates that decreased methylglyoxal levels using the TRPA-1-Nrf-2 pathway. 
Regulatory mechanisms that trigger this detoxification pathway open up avenues for 
therapeutic studies. Candidates were utilized to determine their therapeutic efficacy in 
mammalian in vitro studies, in the background of methylglyoxal stress. In this work, we 
pursue combinational therapy to identify a more effective approach at mitigating 
neurotoxicity. We show that a five-compound combination ameliorates methylglyoxal 
stress in multiple dopaminergic cell lines: N27, PC12 and SH-SY5Y. Results indicate 
that combinational therapy counteracts methylglyoxal stress more effectively than 
compounds used in isolation. Data suggests that the five-compound mixture can be used 






1. Validate individual candidates from drug screen in mammalian cell culture. 
We will expose dopaminergic cells to an α-dicarbonyl (methylglyoxal) in order to 
cause neuronal damage; cells will exhibit neurite retraction. 6 different concentrations:  
(1 nM, 10 nM, 100 nM, 1µM, 10 µM, 100 µM) of each individual compound, from the 
drug screen, will be tested. At 5 different time points (0 hr, 3 hr, 6 hr, 12 hr, and 24 hr) 
photos will be taken. We will measure the neurite length, using Image J software, to 
determine if the compounds prevent the cells neurite from retracting. We hypothesize that 
the compounds will rescue cells from methylglyoxal-induced neuronal damage, 
essentially preserving the cells neurite length. Once all the compounds are tested, we will 
identify eight compounds that rescue neuronal damage. We will focus on one specific 
time point that works best. 
2. Test various compound combinations to identify a more effective approach in 
ameliorating methylglyoxal stress. 
Our hypothesis is that a combination of compounds will serve as a better therapeutic 
for ameliorating methylglyoxal stress. Using the N27 cell line, 6 different concentrations 
of double, triple, and quadruple and quintuple combinations will be tested at 24 hours and 
the neurite length will be quantified. We will determine if the combination alleviates 
methylglyoxal-induced neurotoxicity better than the individual compounds. 
3. Test the best combination in various cell lines to confirm its therapeutic efficacy. 
Once we identify the two best combinations using the N27 cell line, we will test the 
combination in two additional cell lines: PC12 and SH-SY5Y. This will confirm that the 
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combination protects cells against methylglyoxal neuronal damage. We will test each 
combination at 6 different concentrations: 1 nM, 10 nM, 100 nM, 1 µM, 10 µM, 100 µM. 
We will measure the neurite length, using Image J software to determine if the 
compounds are able to prevent retraction of the neurite. 
4. Test the best compound combination in various cell lines to investigate its 
neuroprotective capacity against MPP
+
-induced cellular damage.  
We will test the two best combinations in N27, PC12 and SH-SY5Y cell lines to 
study its neuroprotective capacity against a neurotoxin, MPP
+
.  We will test each 
combination at 6 different concentrations: 1 nM, 10 nM, 100 nM, 1 µM, 10 µM, 100 µM. 
We will measure the neurite length, using Image J software to determine if the 













Aging is a major risk factor for a number of diseases including diabetes. Diabetes 
mellitus (DM) is a metabolic disorder characterized by high blood glucose levels. This 
can be a result of environmental or genetic factors. Metabolism of fat, protein and 
carbohydrates are affected by DM, resulting in deficiencies in insulin secretion in type 1 
diabetes (1). Type 2 diabetes arises from multiple factors, including; insulin resistance, 
obesity, and hyperglycemia. While patients with type 2 diabetes can control their 
glycemic levels, the disease still progresses. This indicates that there is an underlying 
mechanism responsible for DM progression independent of insulin and glucose (2). Due 
to the amount of people who are diagnosed with DM, there is rising concern about a 
global diabetes epidemic (3). In 2014, 366 million adults and children were reported to 
have diabetes worldwide (4). Diabetes mellitus has long-term effects including injury, 
and failure or dysfunction of several organs. Long-term diabetes increases the risk of 
developing multiple secondary complications including: nephropathy resulting in renal 
failure, retinopathy resulting in vision loss, peripheral neuropathy resulting in nerve pain, 
foot amputation, ulcers, and cardiomyopathy resulting in cardiovascular dysfunctions (5). 
The molecular cause of type 2 diabetes and secondary pathologies are not fully 
understood, here we focus on the underlying mechanism.  
 By studying the mechanisms that dictate the onset of diabetes, we open avenues to 
identify novel methods that may be used to counter secondary pathologies. Chronic 
hyperglycemia, lipid peroxidation, and anaerobic glycolysis form unavoidable 
byproducts, called α-dicarbonyls (α-DC) (Figure 1) (6). Increased levels of α-dicarbonyls 
like methylglyoxal (MGO), glyoxal (GO) and 3-deoxyglucasone (3-DG), have been 
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Figure 1: Formation of α-dicarbonyls (e.g. methylglyoxal/MGO).  
Methylglyoxal is an unavoidable byproduct of glycolysis. Fragmentations of 
glycolytic intermediates glyceraldehyde-3-phosphate and dihydroxyacetone 
phosphate produce α-dicarbonyls such as, methylglyoxal. 
 
found in the blood plasma of patients with diabetes (7). α-dicarbonyls are toxic 
metabolites and potent glycation agents that bind with DNA, lipids, and proteins causing 
irreversible damage, ultimately altering the function and structure of these 
macromolecules (8). In this thesis, MGO is a α-dicarbonyl we primarily focus on to study 
its influence on diabetic pathologies. Methylglyoxal is an environmental and/or bacterial 
toxin that is spontaneously formed from triosephosphates with anaerobic glycolysis (9). 
The increased production of MGO and the impaired function in detoxifying this toxic, 
reactive metabolite could cause type 2 diabetes, and therefore be the reason why we 













Figure 2: Methylglyoxal-derived advanced glycation end-products (AGEs) mediate 
age-associated pathologies. 
This figure illustrates the formation of methylglyoxal-derived AGEs: Nε-carboxyethyl-
lysine/CEL and methylglyoxal-hydroimidazolone/MG-H1. The accumulation of AGEs in 
various tissues results in a variety of disease.  
Hyperglycemia generates the endogenous metabolite, MGO, which is responsible 
for the glycation of proteins (10). Glycation is a process that occurs non-enzymatically. 
MGO interacts with arginine and lysine residues of macromolecules, forming advanced 
glycation end products (AGEs) (Figure 2) (11). High levels of exogenous MGO 
administration have been studied in both in vivo and in vitro models, resulting in 
hypercholesterolemia, insulin resistance, accumulation of collagen in kidneys, and 
microvascular degeneration (12–14). MGO has shown to directly increase the amount of 
reactive oxidative species, resulting in cell death (15). Oxidative stress and AGE 
accumulation induces hyperglycemia, playing a contributing role to the development of 












The accumulation of AGEs, such as Nε-carboxyethyl-lysine (CEL) and 
methylglyoxal hydroimidazolone (MG-H1), is a causal risk factor for the rate of aging, 
ultimately modulating lifespan. Not only are AGEs generated endogenously, they are 
found in dietary sources as well. AGEs are abundant in animal-based foods that are rich 
in fat and protein when cooked at dry and high temperatures (17). AGEs crosslink 
proteins, causing an alteration in the protein’s structure and function, and resulting in a 
diverse range of post translational modifications (17,18). AGEs not only derive from 
hyperglycemia, but are also generated as a result of increased oxidative stress even in the 
absence of high glucose levels. AGEs derived from dietary sources has been shown to 
exacerbate diabetic complications, causing accumulation of pro-inflammatory factors 
(19). AGEs are enzymatically broken down by the human body and eliminated through 
the kidneys (17). Accumulation of AGEs is abundant in serum and tissues, driving the 
development of diabetes complications and neurodegenerative disorders (20,21) (Figure 
2). AGEs tend to build up in the central nervous system, targeting areas with marked 
pathologies like the substantia nigra during Parkinson’s disease (17).  
α-Dicarbonyls are precursors of AGEs, forming three structural isomers that are 
ligands for the receptor of AGEs, referred to as RAGEs (22). AGE-associated pathologies 
are largely due to the activation of RAGEs (23). AGEs exert their effects upon binding to 
their receptor, RAGEs then induce intracellular signaling, inflammatory cytokines, and 
free radicals (10). This cascade stimulates inflammation and tissue injury, influencing the 





Approximately 30-50 percent of diabetic patients develop neuropathy as a 
secondary complication, making it one of the most common diabetic complications. 
Diabetic peripheral neuropathy occurs with aging, long term diabetes, lack of glycemic 
control, high blood pressure and elevated levels of lipid (26). Current studies are looking 
to prevent diabetic neuropathy by controlling glycemic levels (27). Roughly 16 percent of 
diabetic patients experience neuropathic pain (28). Hyperglycemia-induced oxidative 
stress promotes apoptosis of nerves, which leads to the pathogenesis of diabetic 
neuropathy (29). The accumulation of AGEs and their contributing role to oxidative 
stress have shown to be a mechanism involved in the pathogenesis of diabetic neuropathy 
(30). Increased oxidative stress results in impaired neural function, causing apoptosis of 
neurons, Schwann cells and glial cells located in the peripheral nervous system (31). 
Glycation of molecules present in the extracellular matrix impairs regeneration of 
neurons, inhibiting them from reproducing and influencing further damage (32). Loss of 
large and small nerve fibers can drive early signs of peripheral neuropathy, including: 
loss of vibratory sensation, altered proprioception, impairment of pain and sensitivity to 
touch. Patients who suffer from diabetic peripheral neuropathy develop symptoms such 
as sensory loss, numbness and stabbing/shooting sensation. Furthermore, sensory loss 
increases patient’s risk for foot injury such as foot/leg infections and ulcers, which may 
lead to amputation of limbs. Diabetic peripheral neuropathy begins in the toes and works 
its way up the body, affecting the upper limbs (31). Symptoms such as altered 
proprioception cause imbalance and increase the risk of falling (33). The development of 
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these painful neuropathy symptoms hinders patients from performing normal daily 
activities and decreases quality of life. 
Parkinson’s disease (PD) 
We study the link between diabetes and Parkinson’s disease by recapitulating 
methylglyoxal-induced pathologies in vitro. Several epidemiological studies have linked 
hyperglycemia as a risk factor for Parkinson’s Diseases (34). Parkinson’s disease is a 
chronic neurodegenerative disorder characterized by the loss of dopaminergic neurons in 
the substantia nigra, located in the midbrain region (35). Depleted levels of dopaminergic 
activity in the striatum disable the coordination of movement, a major hallmark observed 
in Parkinson’s patients (36). The neurodegeneration found in Parkinson’s results from 
mitochondrial dysfunction and oxidative stress (36). Patients who suffer from 
Parkinson’s disease develop symptoms such as bradykinesia, rigidity, resting tremor, and 
postural instability (37). Also, the development of PD can be largely due to the increased 
amounts of AGEs and receptor for AGEs (RAGEs) that have been found in the frontal 
cortex of patients. AGE production induces inflammation as a downstream effect, making 
it a key mechanism contributing to disease pathology. Damage caused by AGEs and the 
accumulation of aggregates results in cellular stress and neuronal death, in addition to a 
decline in proteostasis (38). Notably, the buildup of AGEs and its influence on 
neurodegeneration has led us to focus on the glyoxalase system as a potential therapeutic 
target to mediate AGEs formation and hinder AGEs-associated pathologies.   
Studies have shown that therapies that benefit diabetic patients also show healing 
effects in PD patients (39). 1-Methy-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
toxicity has become a popular model for studying Parkinson’s disease (40). In mice, 
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MPTP damages dopaminergic neurons in the substantia nigra and induces Parkinson’s 
like symptoms (41). When MPTP oxidizes to 1-methyl-4-phenylpyridinium (MPP
+
), the 
product is toxic. When MPP
+
 is taken up by dopaminergic cells, MPP
+
 interferes with 
mitochondrial respiration; hindering ATP formation and inducing oxidative stress. MPP
+
 
also disrupts calcium homeostasis, causing cellular damage (40). 
MPTP is often used as a neurotoxin to induce a Parkinson’s disease phenotype in 
animal models. Upon injection of MPTP, the mitochondrial complex I activity is 
inhibited and striatal dopaminergic neurons undergo cell death (41). Deletion of RAGE 
attenuated MPTP-related cell toxicity, reduced the pro-inflammatory effects caused by 
RAGE, and ultimately hindered the progression of PD (24).  
α-Dicarbonyls detoxification 
In this thesis, we focus on the underlying cause of the diabetes and 
neurodegenerative disorders. It is important to prevent toxic metabolites such as, reactive 
α-dicarbonyls, by enhancing a conserved detoxification mechanism. The abundance of α-
dicarbonyls overwhelms the glyoxalase system and hinders the detoxification process (9).  
It is important to understand the mechanism that regulates stress response when α-
dicarbonyls are present, as their detoxification is critical for limiting AGE formation. 
Previous research identified a conserved TRPA-1-Nrf2 signaling pathway, essential for 
the detoxification of α-dicarbonyls (Figure 3) (6). Upon activation of TRPA-1, the SKN-
1/NRF-2 transcription factors upregulate the evolutionary conserved group of 
glyoxalases: glutathione-dependent (GLO1 and GLO2) and glutathione-independent 
(DJ1). These enzymes are responsible for catalyzing the detoxifying reaction by 




Figure 3: Overview of TRPA-1-Nrf-2 detoxification mechanism.  
TRPA-1 receptor senses α-dicarbonyls (α-DC), causing a calcium influx, which 
activates SKN-1/Nrf-2 transcription factors, upregulating the conserved glyoxalases: 
GLO1, GlO2 and DJ1. The glyoxalases catalyze the reaction that detoxifies reactive α-
DC (e.g. methylglyoxal) to D-Lactate. 
 
lactate (Figure 4) (3). MGO can be detoxified via the glyoxalase system (GLO1 and 
GLO2), dependent on the amount of reduced glutathione. However, under oxidative 
stress conditions the amount of reduced glutathione decreases, ultimately having a 









Studies in mice have shown that impairment in GLO1 function result in 
hyperalgesia and nephropathy, which are symptoms found in patients suffering from 
diabetes (43,44). Furthermore, GLO1 impairment has also been shown to cause coronary 
artery disease and hypertension, evidence that a compromised detoxification mechanism 
induces secondary diabetic pathologies (45,46). 
Glutathione-independent glyoxalase, DJ1, plays a critical role in the 
detoxification of α-dicarbonyls and is a genetic cause of early initiation of Parkinson’s 
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Figure 4: Glyoxalase system detoxifies methylglyoxal. 
Methylglyoxal is detoxified to a less reactive product known as, D-lactate via 
glyoxalase system. Methylglyoxal detoxification occurs both independently and 
dependently on glutathione. Glutathione-dependent glyoxalase pathway is mediated by 
enzymes: glyoxalase 1 (GLO1) and glyoxalase 2 (GLO2).  Glutathione-independent 
glyoxalase pathway is mediated by DJ1. 
 
disease (47). DJ1 is known for exhibiting neuroprotective properties against oxidative 
stress by reducing levels of reactive oxygen species and inhibiting cell death. DJ1 is also 
responsible for regulating dopamine synthesis. In addition to oxidative stress, with aging, 
DJ1 activity becomes impaired and has been associated with the pathogenesis of PD (36). 
Findings that DJ1 is involved in neurodegenerative disease allow researchers to study its 
neuroprotective role as a method for detoxifying α-dicarbonyls and preventing formation 














Previous research showed that exogenous administration of MGO caused C. 
elegans to develop hyperesthesia; a phenotype that mimicked diabetic complications. 
This further suggests that high levels of MGO are implicated in the progression of 
secondary pathologies (6). A high-throughput drug screen was performed to mitigate 
methylglyoxal toxicity in C.elegans, which revealed several candidate ‘supplement-
grade’ compounds that are essentially safe for human consumption (6). Metabolomics 
analysis indicated that the compounds decreased levels of MGO and reversed the 
phenotype. They later determined their mechanism of action and concluded that the 
compounds lowered methylglyoxal levels via the TRPA-1-Nrf-2 pathway. Now that we 
understand the importance of glyoxalases in the detoxification of MGO, we can explore 
new avenues to study regulators of the glyoxalases as a potential treatment for MGO-
mediated pathologies. Here, we validated the therapeutic efficacy of compounds found in 
the previous drug screen and further investigated their role on the detoxification of α-
dicarbonyls in mammalian in vitro studies. 
Combinational therapy 
 Due to the fact that diabetes is a progressive disorder, the use of single agents for 
treatment has been inadequate at controlling glycemic levels (48). Combinational therapy 
involving two or more agents is required for patients with type 2 diabetes to achieve 
lower glycemic levels (49). 
 Studies have shown that some compounds, when taken in combination improved 
glycemic control, lipid profiles, and prevented weight gain. They also showed that the 
combination worked to lower total cholesterol and free fatty acids (50). Combinational 
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therapy has been used in diabetic rats to halt the progression of diabetic neuropathy (51). 
In addition, the combination significantly reduced blood glucose levels and renal injury. 
This study also investigated the role that this combination had in decreasing oxidative 
stress and inhibiting inflammation. They discovered that the combination was a useful 
tool in reducing lipid peroxidation and inhibiting inflammatory cascade in diabetic rats. 
Researchers have used a combination of natural compounds to investigate their 
therapeutic effects against MPTP-induced neurotoxicity (41). They saw that one of the 
compounds when used alone showed positive effects, but when used in combination, led 
to dramatic improvement in motor dysfunction, restoration of striatal neurotransmitter 
signaling, and reversal of depleted levels of nigrostriatal dopamine. 
A combination of two compounds that induces GLO1 activity was used in a 
clinical trial on overweight and obese patients (52). The compounds administered 
individually were ineffective, but a combination of the two compounds improved insulin 
sensitivity in obese patients, increased clearance of methylglyoxal in the plasma of 
overweight patients and promoted weight loss and vascular health.    
We are asking whether these supplement-grade compounds also work to mitigate 
α-dicarbonyl stress in humans/patients suffering from neuropathy as a result of long-term 





Targeting MGO detoxification and prevention of AGE formation as a therapeutic 
approach 
 The increased production of glycating agents such as MGO is one of the main 
pathogenic mechanisms that lead to secondary complications associated with diabetes. 
Since MGO is still being produced, independent of blood glucose levels, a potential 
approach to attenuate its damaging effects is to inhibit the glycation reaction using 
“scavengers” (53). Scavengers are capable of interacting with MGO, essentially 
interfering with the glycation action and trapping it. This approach ultimately prevents 
the formation of AGEs and therefore impedes the development of secondary 
complications (54). The use of scavengers has shown to be beneficial in reducing levels 
of AGEs in various tissues and improving function of peripheral nerves in diabetic 
animals. Administration of these compounds to Type 2 diabetic patients have shown that 
they are effective at reducing MGO levels in blood plasma. Moreover, compounds that 
act as scavengers also have the ability to alleviate oxidative stress and increase the 
production of glutathione, which is essential for the detoxification of MGO via the 
glyoxalase system. 
 When exogenous MGO is administered to rats, scavenger compounds have been 
used as a treatment to decrease levels of AGES in adipose tissue (55). Both, in vivo and 
in vitro studies have shown that these compounds inhibit the formation of AGEs by 
scavenging α-dicarbonyl intermediates (56–58). They also have been shown to improve 
peripheral nerve function in diabetic rats by reducing AGE levels in tissue (59). Thus, 
these compounds are preventing AGE formation by directly reducing MGO levels with 
the aid of MGO scavenging and/or inducing activity of the glyoxalases.  
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 AGE accumulation contributes to the pathogenesis of diabetic complications, 
leading to the development of therapies that hinder AGE formation. Combinational 
therapy has been used to decrease the levels of AGEs in the serum of diabetic mice, while 
monotherapy was not effective at all (60).  
In this thesis, we determined the effects that single and combinational 
supplementation had on the MGO detoxification to prevent formation of AGEs. We used 
three different dopaminergic neuronal cell lines: N27, PC12 and SH-SY5Y. N27 is a cell 
line derived from the mesencephalic tissue of the rat and is used as a dopaminergic 
neuron model for in vitro studies (61). PC12, a rat cell line derived from the adrenal 
phaeochromocytoma, is used to study neurodegeneration (62). Finally, SH-SY5Y is a 
human cell line derived from a neuroblast from neural tissue, this cell line has become a 
popular cell model for PD research (63).  
Our central focus is making these supplement-grade compounds relevant to 
human health by creating a supplement that can be readily available to patients. Oxidative 
stress is associated with both diabetes and Parkinson’s disease, suggesting antioxidant 
properties within our supplement may prevent its detrimental effects. Antioxidant therapy 
can restore glutathione levels, enhancing the glyoxalase system and increasing the 
detoxification of MGO. We also seek to utilize compounds that possess neuroprotective 
properties. The combination we intend to create includes classes of compounds that have 
the same mechanism of action, the TRPA-1-Nrf-2 pathway which is responsible for 
regulating methylglyoxal detoxification.  
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The individual compounds have been previously used in various studies as 
supplements and have been shown to benefit diabetes and/or age-associated diseases. In 
this study we test several combinations to counteract methylglyoxal-induced and MPP
+
-
induced cellular damage in: N27, PC12 and SH-SY5Y cell lines. We have identified 
combinations that are more effective than the respective compounds administered 
individually. We chose a five drug mixture made up of L+N+T+Pi+Py. This compound 
mixture can be used to mitigate methylglyoxal-induced and MPP
+
-induced neurotoxicity 
in vitro, and was shown to be more effective than the individual compounds tested. This 
study has given us the ability to further investigate the therapeutic effects of compound 
mixtures by administering them as a supplement to a diabetic mouse model. We believe 
that combinational therapy can mitigate α-dicarbonyl levels and prevent the onset of 
neurodegenerative disorders and diabetic complications such as neuropathy, 










Material and Methods 
Growth and differentiation of N27 cell line:  
 N27 dopaminergic cells were grown in Corning® RPMI 1640 L-media containing 
L-glutamine (Mediatech, Inc. Manassas, VA, USA) and 10% Fetal Bovine Serum (FBS; 
Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Cells were incubated at 
37˚C in a humidified air atmosphere containing 5% CO2. 
 Neurite elongation was induced by addition of 1 mM of dibutyryl-cAMP (Enzo 
Life Sciences, Inc. Farmingdale, NY, USA) into the cell culture media. 48-72 hours 
following dibutyryl-cAMP treatment, cells exhibited extended neurites.   
Growth and differentiation SH-SY5Y cell line:  
 The SH-SY5Y cells were grown in Dulbecco's modified Eagle's medium 
(DMEM; Hyclone; GE Healthcare Life Sciences, Logan UT, USA) and 10% heat-
inactivated fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA). Cells were incubated at 37˚C in a humidified air atmosphere containing 5% 
CO2. 
Differentiation and neurite elongation was induced by addition of 10 µM of 
Retinoic Acid (Sigma-Aldrich, St. Louis, MO, USA) into the cell culture medium for 72 
hours. 80 nM of 12-O-Tetradedanoylphorbol 13-acetate (Sigma-Aldrich, St. Louis, MO, 
USA) was administrated to the cell culture medium for an additional 72 hours. 
Growth and differentiation PC12 cell line:  
  PC12 cells were grown in Dulbecco’s Modification of Eagles Medium 4.5 g/L 
glucose, L-glutamine, sodium pyruvate (DMEM, 1X; Mediatech, Inc. Manassas, VA, 
USA), 10% HI inactivated Horse Serum (Gibco; Thermo Fisher Scientific, Inc., 
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Waltham, MA, USA) and 5% heat-inactivated fetal bovine serum (FBS; Gibco; Thermo 
Fisher Scientific, Inc., Waltham, MA, USA). Cells were incubated at 37˚C in a 
humidified air atmosphere containing 5% CO2. 
Differentiation and neurite elongation as induced by the addition of 50 ng/mL 
Corning® 7S Nerve Growth Factor, Mouse Natural (NGF; Discovery Labware, Inc. 
Bedford, MA, USA) to the cell culture media for 48-72 hours.  
Neurite Length Imaging and Quantification 
Cells were analyzed at 0, 3, 6, 12 and 24 hour after treatment with compounds. 
Cells were imaged with a Nikon Ti-Eclipse Perfect Focus System inverted microscope, 
equipped with a Cascase 512B camera (Photometrics, Tuscon, AZ).  Quantification of 
neurite outgrowth of 75-100 randomly selected cells was done by manually measuring 
the length of a projection from the edge of the cell body (see Figure 4). One neurite of 
one individual cell will be quantified using Image J software (http://imagej.nih.gov/ij/). 
Compound Administration under Methylglyoxal-Induced stress 
Methylglyoxal (Sigma-Aldrich Corporation, St. Louis, MO, USA) was added at a 
concentration of 125 µM and individual drugs were administered in a dose dependent 
manner at increasing 10 fold increments starting from 1nM to 100 µM for 24 hours post 
differentiation. Ethanol and water was used as a vehicle control. Cells were imaged and 






Combination Administration under Methylglyoxal-Induced Stress  
Methylglyoxal (Sigma-Aldrich Corporation, St. Louis, MO, USA) was added at a 
concentration of 125 µM in PC12 and N27 cell lines and 250 µM for the SH-SY5Y cell 
line. The combinations were administered for 24 hours post differentiation. The 
combinations were tested at 6 different concentrations: 1 nM, 10 nM, 100 nM, 1 µM, 10 
µM and 100 µM. The two-compound combinations were comprised of equal amounts of 
two different compounds, essentially a 1:1 ratio mixture at all the above total 
concentrations as well. The three-compound mixture was comprised of an equal amount 
of each of the different compounds making up a 1:1:1 ratio. The four-compound mixture 
was made up of equal amounts of four different compounds. The five-compound mixture 
included a 1:1:1:1:1 ratio of five different compounds. When altering the volume of the 
each of compounds found in the five-compound combination, the mixture comprised of a 
3:0.5:0.5:0.5:0.5 ratio.  
Combination Administration under MPP
+
 induced Neuronal Stress 
 MPP
+
, 1-Methyl-4-phenylpyridinium iodide, (Sigma-Aldrich Corporation, St. 
Louis, MO, USA) was added at a concentration of 250 µM in PC12 and N27 cell lines 
and 300 µM in the SH-SY5Y cell line. The single compounds and combinations were 
administered for 24 hours post differentiation at 6 different concentrations: 1 nM, 10 nM, 
100 nM, 1 µM, 10 µM and 100 µM. 
Statistical Analysis 
Data analyses performed using GraphPad Prism (GraphPad Software version 
6.00. Inc., La Jolla, CA). Neurite length statistical comparison was performed using non-
parametric Mann-Whitney Test. Neurite length was subjected to one-way ANOVA. 
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Pairwise comparisons for data quantification and significance were done using two-tailed 
Student’s t-tests. (Significance: *P<0.05, **P<0.01, ***P<0.001). GraphPad Prism was 
used to graph dose-dependent response curves using parametric logistic algorism. Data 























Figure 6: Neurite length Quantification.  
Neurite (red dotted line) is defined as a thin projection longer than the diameter of the 
associate cell body is measured using Image J software. (Image used from Sana Khateeb) 
Results 
First the cells are differentiated using dibutyryl-cAMP, Nerve Growth Factor, 
Retinoic Acid, or TPA, respectively. Upon differentiation, the cells exhibit long, 
extended neurites. The long neurites allow the cells to communicate with neighboring 
cells and allow for synapses to occur. However, when we add methylglyoxal to the cell 
culture media, we see the methylglyoxal causes neuronal damage, characterized by 
retraction of neurites length (Figure 5).  We randomly measured 100 neurites; only the 
length of one neurite was measured of each individual cell as traced with the red dotted 













Figure 5: Methylglyoxal-induced neuronal damage in vitro.  
Images of differentiated N27 cells exhibit long, extended neurites (red arrows). 
Administration of MGO causes retraction of neurite outgrowth and diminishes neuronal 
networks, as seen on far right image. (Image used from Sana Khateeb) 
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A high-throughput drug screen was performed in C. elegans using supplement 
grade compounds to mitigate α-dicarbonyl levels. Using the same compounds examined 
in C. elegans, we validated their therapeutic efficacy in vitro. We tested the 
neuroprotective capacity of several supplement-grade compounds: B, Py, NA, N, VD, T, 
Py, L, A, and CA. There were 6 different concentrations used: 1nM, 10nM, 100nM, 
1µM, 10µM and 100µM. We measured the therapeutic efficacy of each against 125 µM 
MGO at 0, 3, 6, 12 and 24 hours. All compounds administered at 12 and 24 hours showed 
effective rescue of neuronal damage. Ethanol was used as a vehicle control.  When we 
used these supplement-grade compounds in the background of MGO stress, we saw that 
individual compounds work to ameliorate MGO neuronal damage. However, we see that 
the individual compounds never reached full rescue of the neurite length as compared to 
control at 12 and 24 hours (Figure 7). We then decided to combine two compounds to 


































































































































































































































































































































































































































































































































































































































Figure 7: Quantification of neuroprotective capacity against methylglyoxal-induced 
damage.  
Quantification of the single compounds: (A, B, CA, VD, L, N, NA, Pi, Py and T) 
therapeutic efficacy against MGO-induced neurotoxicity. Neurite length quantification in 
N27 neuronal cells, treated with EtOH or water (control), 125 µM MGO, and increasing 
concentrations (1nM, 10nM, 100 nM, 1 µM, 10 µM, or 100 µM)  of single compounds + 




Using the compounds that were shown to have the most neuroprotective effect in 
our MGO-stress assay (Figure 3), L, N and Py, we tested a total of four different 
combinations consisting of two compounds each. The combination included both 
compounds in a 1:1 ratio. The two compounds were used singly as a baseline control. 
The first combination of N+L was more effective than the L and N singles at every 
concentration, nearly reached full recovery at 10 µM. Py worked better than L and N did 
individually. The combination Py+N, was not able to enhance its efficacy; in fact it acted 
similarly to individual compounds. However, the combination of Py+L worked better 
than the two single compounds at every concentration except 10 µM (Figure 8A). A 
dose-response curve was generated relative to 125µM MGO neurite length (Figure 8B). 
From the two-compound combinations, we saw that L+N and Py+L worked best out of 















Figure 8: Quantification of two-compound combination therapeutic capacity against 
MGO-induced toxicity.  
(A) Neurite length quantification in N27 cells, treated with EtOH/water (control), 125 µM 
MGO, and (1nM, 10nM, 100 nM, 1 µM, 10 µM, or 100 µM) compounds/combination 
+125 µM MGO.  
(B) Dose response curves for neurite length relative to 125 µM MGO treated cells. In each 
graph, the dotted line represents the mixture of the two compounds and the solid line 





















From the three two-compound combinations we tested, the N+L mixture, and the 
L+Py mixture were the most effective two-compound combinations. We used L+N and 
Py+L as the combinations for a baseline to compare all the three-compound 
combinations.  We tested several three-compound mixtures using a 1:1:1 ratio of each 
compound. We saw that neither (L+N+Ni) nor (L+N+A) worked as effectively as the 












































































































































































































































































































































































































































































































































































































































































combination, we saw that L+N+Py and L+N+T were more effective than the two-
compound combination at every concentration. When compared to L+Py, we see that 
most of the three-drug combinations worked similarly to the two-compound mixture, 
indicating that the three-compound mixtures were not enhancing its overall efficacy 
(Figure 9A). A dose response curve was generated relative to 125µM MGO neurite 
length (Figure 9B). Only the combinations of L+N+T and L+N+Py, worked more 






















Figure 9: Neuroprotective quantification of three-compound combination.  
(A) Neurite length quantification in N27 cells, treated with EtOH (control), 125 µM 
MGO, and (1nM, 10nM, 100 nM, 1 µM, 10 µM, or 100 µM) combination + 125 µM 
MGO.  
(B) Dose response curves for neurite length relative to 125 µM MGO treated cells. In 
each graph, the red line represents the double combination (serving as a value for 



































































































































































































































































































































































































































































From the 13 three-compound combinations we tested, we saw that the L+N+T 
mixture and the L+N+Py mixture were the more effective triple combinations at every 
concentration. We used L+N+T and L+N+Py to compare to our four-compound mixtures. 
We tested several four-compound mixtures using a 1:1:1:1 ratio of each compound. We 
see that at 1 nm and 10 nm the L+N+T+Pi combinations acts similar to the L+N+T 
combination. However, starting at 100 nm we see that the combination dramatically 
enhances the efficacy. And we see that the L+N+T+Py combination works similar to the 
three-compound mixture. Moreover, when we used L+N+Py as a control to test the other 
four-compound mixture, L+N+Py+Pi, we see that at the nM concentrations it in fact 
works less effective than the three-compound mixture, but starting at 1 µM it started to 
increase and work more effectively than the three-compound mixture (Figure 10A). A 
dose-response curve was generated relative to 125µM MGO neurite length (Figure 10B). 
We see that the combination of L, N, T and Pi worked more effectively than the L, N and 










































































































































































































































































































Figure 10: Quantification of four-compound combination therapeutic capacity. 
(A) Neurite length quantification in N27 dopaminergic neuronal cells, treated with 
EtOH (control), 125 µM MGO, and (1nM, 10nM, 100 nM, 1 µM, 10 µM, or 100 µM) 
combination + 125 µM MGO.  
(B) Dose response curves for neurite length relative to 125 µM MGO treated cells. In 
each graph, the red line represents the triple combination (serving as a value for 




















We used all three, four-compound mixtures to compare the efficacy of the five-
compound mixtures. We saw that L+N+T+Py+Pi worked best to overcome MGO-
induced neurotoxicity at low concentrations and we see a significant difference compared 
to the rest starting at 1 µM (Figure 11A).   A dose-response curve was generated relative 




Figure 11: Neuroprotective quantification of five-compound combination.  
(A) Neurite length quantification in rat dopaminergic neuronal cells, treated with EtOH 
(control), 125 µM MGO, and (1nM, 10nM, 100 nM, 1 µM, 10 µM, or 100 µM) 
combination + 125 µM MGO.  
(B) Dose response curves for neurite length relative to 125 µM MGO treated cells. Red, 
green, and magenta lines represent the quadruple combinations (serving as values for 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Using this five-compound combination we decided to alter the amount of each 
compound we use in the mixture; essentially, increasing the amount of one compound 
while decreasing the amount of the remaining four compounds. We tested the 
3:0.5:0.5:0.5:0.5 ratio combinations and compared them to 1:1:1:1:1 ratio five compound 
combinations. We saw that the LNTPyPi equal volumes worked almost the same as the 
(Pi)+L+N+T+Py, however, the altered combination with the increased amount of Pi 
worked better at lower concentrations, ultimately reaching a higher maximum value than 
the combination with equal amounts (Figure 12A). A dose response curve was generated 
relative to 125µM MGO neurite length (Figure 12B). We concluded that increasing the 
amount of Pi and equally decreasing the amount of L, T, N and Py showed a more 















Figure 12: Altered concentrations of each compound demonstrates a more effective 
approach at mitigating methylglyoxal-induced toxicity 
(A) Neurite length quantification in N27 cells treated with EtOH (control), 125 µM MGO, 
and (1nM, 10nM, 100 nM, 1 µM, 10 µM, or 100 µM) combination + 125 µM MGO.  
(B) Dose response curves for neurite length relative to 125 µM MGO treated cells. The red 
line represents the five-compound combination with equal concentrations of each 
compound.  The assorted color lines represent the combination with altered concentrations, 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We saw that the two, five-compound mixtures worked really well to alleviate 
MGO stress in the N27 cell line, so, we wanted to test this phenomenon in different 
dopaminergic cell lines: PC12 and SH-SY5Y. When we tested the equal ratio 
combination and the best-altered ratio combination, increased amount of Pi, in the PC12 
cell line, we saw that at 1 µM the L+N+T+Py+(Pi) combination was more effective than 
the L+N+T+Py+Pi combination that was comprised of equal volumes of each compound. 
When we tested these two different five-compound combinations in the human cell line, 
SH-SY5Y, we saw that at 100 nM the altered mix, L+N+T+Py+(Pi), works better than 
the compound with equal volumes (Figure 13A). A dose response curve was generated 
relative to 125µM MGO neurite length (Figure 13B). We saw that these combinations 













Figure 13: Five-compound mixtures counteract methylglyoxal-induced cellular 
damage in PC12 and SH-SY5Y cell lines.  
(A) Neurite length quantification in rat/human dopaminergic neuronal cells, treated 
with EtOH (control), 125/250 µM MGO, and (1nM, 10nM, 100 nM, 1 µM, 10 µM, 
or 100 µM) combination + 125/250 µM MGO.  
(B) Dose response curves for neurite length relative to 125/250 µM MGO treated 
cells. In each graph, the red line represents the five-compound combination with 
equal concentrations of each compound and the black line represents the combination 












We compared the singles, L and N, to the two different five-compound 
combinations, LNTPyPi and LNTPy(Pi), in three different dopaminergic cell lines, under 
both MGO and MPP+ stress. We see that in the PC12 cell line, the two, five-compound 
mixtures surpass the control value at 1µM and under MPP+ it reached the control value at 
10 µM.  We then used the two best five compound mixtures and compared their 
neuroprotective capacity with the two best individual compounds (Figure 14A). All four 
mixtures were tested under MGO-induced neurotoxicity and MPP
+
-induced 
neurotoxicity. We see that the two compounds alone do not fully rescue MGO and MPP
+
-
induced stress as compared to the control neurite length. However, the two mixtures fully 
rescue MGO and MPP
+




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 14: Five-compound combinations versus single compound under 
methylglyoxal and MPP
+ 
induced neurotoxicity.  
(A) Neurite length quantification in rat/human dopaminergic neuronal cells, treated with 
EtOH (control), 125/250 µM MGO or 250/300 µM MPP
+
, and (1nM, 10nM, 100 nM, 1 




(B) Dose response curves for neurite length relative to 125/250 µM MGO or 250/300 
µM MPP
+
, treated cells. Dotted line represents the relative neurite length of control 
(untreated) cells. The orange and black lines represent the single compounds, 
respectively. The dark and light blue lines represent the two different five-compound 
























































































































































































































































































































































































































































































































In addition to the single compounds, D and P were compounds that also came out 
of the previous drug screen using C. elegans and were tested on other cell lines that 
worked to alleviate MGO-induced damage (data not shown). Efficacy of the two single 
compounds, D and P, was compared to the two five-compound combinations, LNTPyPi 
and LNTPy(Pi), against MGO and MPP
+
 stress in 3 different dopaminergic cell lines 
(Figure 15 A). We saw the D and P work to rescue MGO and MPP
+ 
neuronal damage. 
We see that under MGO stress in N27 and PC12 cell lines, PA works very similar to 
LNTPyPi. However, under all conditions examined we ultimately see that the two five-
compound mixtures works more effectively at overcoming MGO and MPP
+
 neuronal 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 (A) Neurite length quantification in rat/human dopaminergic neuronal cells, treated with 
EtOH (control), 125/250 µM MGO or 250/300 µM MPP
+
, and (1nM, 10nM, 100 nM, 1 µM, 
10 µM, or 100 µM) compounds/combination + 125/250 µM MGO or 250/300 µM MPP
+
 
(B) Dose response curves for neurite length relative to 125/250 µM MGO or 250/300 µM 
MPP
+
, treated cells. On each of the graphs, the red and orange lines represent the single 
























Hyperglycemia and oxidative stress produce toxic byproducts known as, α-
dicarbonyls, which are linked to the pathogenesis of diabetes. High α-dicarbonyls levels 
give rise to advanced glycation end products (AGEs), which seems to be the etiology 
agent of secondary diabetic complications and neurodegenerative disorders such as 
Parkinson’s disease. AGEs and their precursors, α-dicarbonyls, are the subject of studies 
focusing on understanding their influence on the progression of aging and age-associated 
disease. The accumulation of AGEs and the biochemical mechanism as to how they are 
sensed, formed, and detoxified is a major bottleneck in understanding AGEs-related 
pathologies. Our understanding of α-dicarbonyls and AGEs has permitted the 
development of several therapeutic agents. Numerous natural compounds were screened 
for TRPA-1-Nrf2 inducer activity in Caenorhabditis elegans. The drug screen revealed 
several supplement grade compounds that decreased α-dicarbonyls (e.g. 
methylglyoxal/MGO) levels utilizing the TRPA-1-Nrf-2 pathway (6). We see that the 
compounds worked effectively in C. elegans and we went on to test their therapeutic 
efficacy through mammalian in vitro studies. Studying the compound’s rescuing effects 
can help us develop a therapeutic reagent that protects against neurotoxicity. 
We test these compounds to rescue methylglyoxal-induced cellular damage, 
ultimately to prevent the accumulation of AGEs, which seem to be synergistic with 
pathogenic pathways in diabetes. In this study, we focus on methylglyoxal detoxification 
as the therapeutic target. These supplements exert very powerful protective effects, 
allowing us to use these compounds as potential supplement to hinder the progression of 
diabetes and/or Parkinson’s disease. 
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Validate individual candidates from drug screen in mammalian cell culture. 
Previous worm findings emphasized the need for mammalian in vitro studies, to 
validate various supplement-grade compounds in the background of methylglyoxal stress 
and test their neuroprotective capacity in preventing neurite retraction caused by 
methylglyoxal. We identified eight compounds that were protective against 
methylglyoxal-induced neurotoxicity. Quantifying the neurite length of each cell post 
drug administration, we saw that most compounds rescued the neurite retraction caused 
by methylglyoxal within 12 to 24 hours. However, our results show that VD and CA did 
not work to rescue methylglyoxal cellular damage. Although these compounds worked 
well in worms we did not see the same beneficial effect in cell culture. We might not 
have seen the same effect in cell culture because this process is likely not completely 
conserved between worms and cells, therefore, some differences could be expected.   
While our worm data suggests that each compound ultimately bolsters 
methylglyoxal detoxification, they target different parts of the TRPA-1-Nrf2 pathway 
that regulate methylglyoxal detoxification. So, instead of pursuing individual compounds, 
we decided to test various combinations. Some compounds activate SKN1/Nrf-2 both 
independent of and dependent on TRPA-1 suggesting that the compound provides a 
better outcome due to possible crosstalk to synergistically upregulate the glyoxalase for 
functional detoxification of methylglyoxal.  
Test various combinations to identify a more effective approach in ameliorating 
methylglyoxal stress. 
Our goal was to find a unique mixture, by combining the most effective 
compounds in order to identify a combination that will ameliorate methylglyoxal toxicity 
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more effectively than single compounds. Clinical trials have demonstrated that a single 
compound was ineffective at reducing methylglyoxal levels, however, compounds given 
in combination showed clearance of methylglyoxal in the plasma of patients (55). Similar 
to what they have shown, we tested several combinations in mammalian in vitro studies, 
and we saw that the single compounds never fully rescued the length of the neurite as 
compared to the combinations.  Our results showed that when we added five different 
compounds to the mixture not only did we achieve full rescue but the neurite length was 
phenotypically better than the control, indicating that the mixture exhibited robust effects. 
We showed that after meticulously testing many binary, ternary, quaternary 
combinations, the five-compound mixture, which includes L, N, T, Pi, and Py, was most 
effective in ameliorating methylglyoxal-induced stress. We believe that the five-
compound combination enhanced the effectiveness as compared to the other 
combinations we tested because of the addition of Py to the mixture. The Py compound 
acts as α-dicarbonyl scavenger, ultimately inhibiting the formation of AGEs (53), 
therefore, we believe that the addition of this specific compound enhanced its overall 
potency and efficacy, making it the best combination we tested thus far. This data showed 
us that with combinational therapy we were able to successfully counter-act 
methylglyoxal damage. This combination may target an uncharacterized pathway to 
activate either of the glyoxalases, which may be lowering levels of methylglyoxal that 
will simultaneously prevent formation of methylglyoxal-derived AGEs.  
In the L+N+T+Py+Pi mixture, we saw that even at the lowest concentration of the 
mixture (1 nM), which included only 200 pM concentration of each individual drug; the 
mix resulted in significant improvement. It is to our surprise that, in generating this 
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mixture, we effectively reduced each of the individual compounds concentration by 5 
folds, while increasing the overall effectiveness of the treatment (see Figure 11). We 
worked out dosages where we saw that the combination worked at lower concentrations 
and at the maximum effect it worked better than the control. Results suggest that this 
combination can potentially be used as a supplement, reducing the amount of multiple 
agents without undermining the suitable outcome, thereby, minimizing the risk of 
probable side effects. Given evidence that some of the compounds within our mixture 
inhibit glycation, one possible explanation for this effect is inactivating and trapping 
methylglyoxal and consequently reducing methylglyoxal stress (53). Each of the 
compounds possesses antioxidant, scavenging, and neuroprotective properties, suggesting 
that their properties protect against oxidative stress and neuronal toxicity. 
We went on to further test the role this five-compound combination plays in 
halting neuronal damage. We altered the concentrations of each compound within the 
mixture to test for an increase in effectiveness as compared to mixture with equal 
concentrations of each compound. We saw that when we increased the concentration of 
L, N, T, Pi and Py, respectively, most failed to work more effectively than the mixture 
containing equal concentrations of each compound. Surprisingly, we found that when we 
increased amount Pi six times more than the L, N, T and Py it worked very similarly, just 
slightly more effectively than the combination that contained equal amounts of the each 
compound (see Figure 12).  Pi must have enhanced the mixture’s potency when we 
altered the concentration because Pi is known to activate SKN-1/Nrf2 using the TRPA-1 
receptor and signals through DJ1 and GLO1 to reduce methylglyoxal levels and neuronal 
damage (6). Therefore, when we increased the concentration of Pi results indicate that the 
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combination improved the mixtures detoxification capability. This finding suggests that 
Pi is critical for broadening the overall effectiveness of the combination. This 
combination is possibly enhancing the metabolism of α-dicarbonyls by increasing the 
amount of glutathione levels to reduce methylglyoxal stress.    
These findings confirmed that our five-compound combination exerted 
neuroprotective effects and reversed methylglyoxal-induced damage by rescuing neurite 
retraction. We know that some compounds target the TRPA-1 receptor, while others 
independently target the Nrf2 transcription factor that is responsible for upregulating the 
glyoxalase system. Although these compounds in combination may target different parts 
of the TRPA-1 signaling pathway, together they ameliorate methylglyoxal toxicity by 
regulating methylglyoxal detoxification through the activation of the glyoxalases.   
If we had more compounds to work with, for example, if we made a mixture that 
included ten different compounds rather than the five, I believe we would not see any 
further activation of the detoxification pathway. If we were to add more compounds to 
the mixture, I believe the mixtures would start to have similar effects or diminish their 
combined activity. Furthermore, the addition of more compounds to the mixture increases 
the chances of toxicity because each compound is solubilized differently. With more 
compounds, we run the risk that the compounds might not work well due to non-polar, 
polar properties, interference between agents, and/or chemical incompatibilities. Also, 
each compound is absorbed, metabolized, and excreted differently, which might become 





Test the best combination in various cell lines to confirm its therapeutic efficacy. 
 The two five- compound combinations were first identified using N27 cells; we 
saw that the two sets of five-compound mixtures had a significant capacity for 
ameliorating methylglyoxal stress. We then tested this phenomenon to confirm its 
therapeutic efficacy in two different cells lines: PC12 and SH-SY5Y. We see that in the 
cells treated with methylglyoxal, the neurites retract about to about 50 percent of the 
length compared to the untreated control. We saw that in both cells lines, the 
combinations overcame the damaging effects of methylglyoxal while the compounds 
used in isolation failed to reach full rescue. We see that the combinations did not have 
any toxic effects across all three mammalian cell lines, indicating their detoxification 
abilities are robust and broadly applicable. These compounds have been shown to exhibit 
antioxidant and neuroprotective effects in previous in vivo and in vitro studies 
(28,39,41)This unique combination was generated to increase the activity of the 
glyoxalase system, therefore enhancing the detoxification of methylglyoxal to mitigate α-
dicarbonyl toxicity. These studies revealed two five-compound mixtures that had robust 
beneficial effects. The observation establishes combinatorial therapy as the better 
therapeutic approach.  
Since we know that under physiological conditions, methylglyoxal is detoxified 
into a less reactive metabolite, D-lactate, we expect the administration of the 
combinations in the presence of methylglyoxal would result in an increased production of 
D-lactate. Therefore, to show that these combinations enhance the detoxification 
mechanism, a future experiment would be to measure elevated levels of D-lactate. 
Additionally, we would need to identify the combinations mechanism of action, to ensure 
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that the mixture is detoxifying methylglyoxal. A future experiment would be to perform 
RT-PCR to show if the combinations are targeting parts of the TRPA-1-Nrf2 signaling 
pathway.  
Test the best combination in various cell lines to investigate its neuroprotective 
capacity against MPP
+
-induced cellular damage.  
 We tested our combinations under MPP
+ 
stress in multiple cell lines to 
recapitulate the neurodegenerative effect in Parkinson’s disease. We saw that in our 
negative control MPP
+ 
significantly reduced the neurite length of the cells, and the 
combinations rescued MPP
+
-induced neuronal damage. We also compared how effective 
the single compounds were in mitigating MPP
+ 
damage. Results show that although, the 
single compounds ultimately alleviated MPP
+
-induced neuronal stress, they never reach 
full rescue of the neurite length as compared to the control. However, the five-compound 
combination had a stronger therapeutic effect than both of compounds used insolation. 
The combined activity exceeds the total activity of the individual compounds indicating 
that our combination is largely synergistic. These results demonstrate that our 
combination exhibits neuroprotective activity against neurodegeneration in Parkinson’s 
disease through rescue of MPP
+
- induced neuronal damage. We believe to have found the 
best combination that not only mitigates neuronal damage under MGO stress but also 
exerts neuroprotective activity against MPP
+
 stress. These findings show that our 
combination is unique, meaning that it is a mixture that contains a variety of beneficial, 
therapeutic properties working together to protect against the downstream effects of 
MPP
+
, such as apoptosis, oxidative stress, and mitochondrial dysfunction. All, which are 
principal mechanisms, found to be associated with the early onset of both PD and 
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diabetes. And as stated in literature, drugs that are found to alleviate diabetic symptoms 
can also be beneficial for PD (39). 
Validation in several mammalian in vitro studies permits further research in 
diabetic mouse model 
Dose-dependent studies and validation of therapeutic efficacy toward MGO and 
MPP+ toxicity permits rationale for combinational supplementation in mammalian mouse 
model. Mice are often used to model diabetes and AGEs-related pathologies due to their 
relatively close link to human disease biology. In previous studies, individual compounds 
have been used as therapeutic supplements to exhibit anti-inflammatory, neuroprotective, 
and antioxidant effects. Many studies have used these compounds as a single supplement 
to decrease blood glucose levels, and also prevent diabetic complications such as 
cardiomyopathy, and neuropathy as well as nephropathy (29,41,57). However, there is a 
significant need to develop a therapeutic that ameliorates AGE-stress, so we have 
identified a five-compound mixture as a complementary treatment option for diabetic 
pathologies and neurodegenerative disorders, such as Parkinson’s disease. Our 
combination includes many beneficial properties, which can be used as a potential 
therapeutic agent to improve glycemic levels and prevent formation of AGEs, thus 
prohibit secondary pathologies.  
We postulate that the anti-inflammatory and antioxidant properties of the working 
compounds could play a role in their neuroprotective effect. We hope to translate this to 
in vivo studies; combinational and monotherapy has worked before in both clinical and in 
vivo studies (41,64). We believe our combination when used in a diabetic mouse model; 
the combination can potentially prevent diabetic complications by clearing out precursors 
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of AGEs and ultimately inhibiting the formation of AGEs. All these compounds are 
‘supplement-grade’ meaning they are safe for human consumption. This allows for the 
ease of adapting the methods as all are already available. 
Diabetic complications and age-associated neurodegenerative disorders such as 
Parkinson’s diseases currently do not have effective drugs treatments. Current 
therapeutics available for diabetic patients target glucose levels to reach glycemic control. 
However, targeting blood glucose may not prevent the formation of AGEs. Hence, our 
unique supplement mix protects against neuronal damage in vitro, targeting the formation 
of AGEs by mitigating α-dicarbonyl toxicity. Together with current therapeutic is a 
complementary way to prevent the progression of diabetes and treat diabetic 
complications (Figure 16).  
Our combination has the potential to serve as a powerful tool for treatment. 
However, in order to effectively translate our findings and achieve a desirable outcome, 
we need to first assess our results acquired in vitro.  We have to take into account that 
ratios used to generate our combination may change dramatically once administrated to 
mice due differences in metabolism, absorption, distribution, and excretion. We will 
carefully choose a concentration and we are hopeful that our mixture will translate well to 







Figure 16: Five-compound combinations as a possible therapeutic for diabetic 
complications. 
This illustration represents the critical factors that contribute to diabetic complications.  High 
glucose levels lead to the formation of AGEs which accumulate in various tissues resulting in 
diabetes-associated pathologies. Current therapeutic target blood glucose levels and the five-
compound combination target the formation of AGEs. Both, current therapeutic and the five-








Worm, mouse, and cell culture models suggest that AGEs influence diabetic 
complications and neurodegeneration, yielding future studies to understand the 
mechanism involved in modulating AGEs. Our combinations ability to detoxify 
precursors of AGEs suggests that we may have developed a therapeutic that alleviates 
AGEs-associated pathologies. We are moving towards mouse experiments soon and we 
are very hopeful that the mixture will show positive data in vivo. We will be using 
C57BKS db/db and high fat induced diabetes mouse models that exhibit diabetic-related 
complications. We plan to perform various non-invasive assays and histological studies 
to study amelioration of diabetic complications such as diabetic cardiomyopathy, diabetic 
nephropathy and diabetic neuropathy. We believe these compounds will modulate 
cellular stress due to α-dicarbonyls and advanced glycation end products, in turn, 
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